

Therapeutic Drug Monitoring Unit

Title: Guideline for Therapeutic Drug Monitoring of Antiepileptic Drugs

Code: TDM-FRM-SER-010

Version: 1.0

Authors: Sharon Allen-Phillips

Authorised By: Cerian Dance and Sharon Allen-Phillips

Authorised Date: 27-Feb-2026

Review Date: 27-Feb-2028

Document Type: Document

Document Status: Authorised

OU Name: Chalfont Epilepsy Unit

TDM-FRM-SER-010

Guideline for Therapeutic Drug Monitoring of Antiepileptic Drugs

| Antiepileptic Drug | Ideal Sampling Time | Sample Volume (mL) | Time To Steady-state (Days) | Reference Range (mg/L) |
|--|------------------------------|--------------------|-----------------------------|------------------------|
| Brivaracetam | Immediately before oral dose | 0.2 | 1 to 2 | 0.2 to 2.0 |
| Carbamazepine | Immediately before oral dose | 0.2 | 2 to 4 ^A | 4 to 12 |
| Carbamazepine epoxide (pharmacologically active metabolite of carbamazepine) | Immediately before oral dose | 0.2 | 7 ^A | Up to 2.3 |
| Clobazam | Immediately before oral dose | 0.2 | 7 to 10 | 30 to 300 (µg/L) |
| Desmethyl Clobazam (Pharmacologically active metabolite of clobazam) | Immediately before oral dose | 0.2 | 7 to 10 | 300 to 3000 (µg/L) |
| Clonazepam | Immediately before oral dose | 0.2 | 3 to 10 | 20 to 70 (µg/L) |
| Eslicarbazepine | Immediately before oral dose | 0.2 | 3 to 4 | 3 to 5 |
| Ethosuximide | Immediately before oral dose | 0.2 | 8 to 12 | 40 to 100 |
| Felbamate | Immediately before oral dose | 0.2 | 3 to 5 | 30 to 60 |
| Free Carbamazepine | Immediately before oral dose | 0.5 | 2 to 4 ^A | 1 to 3 |
| Free Lamotrigine | Immediately before oral dose | 0.5 | 3 to 8 | 1 to 7 |
| Free Phenobarbital | Immediately before oral dose | 0.5 | 15 to 30 | 5 to 18 |
| Free Phenytoin | Immediately before oral dose | 0.5 | 6 to 21 | 1 to 2 |
| Free Valproic Acid | Immediately before oral dose | 0.5 | 2 to 4 | 5 to 10 |
| Gabapentin | Immediately before oral dose | 0.2 | 1 to 2 | 2 to 20 |
| Lacosamide | Immediately before oral dose | 0.2 | 2 to 3 | 10 to 20 |
| Lamotrigine | Immediately before oral dose | 0.2 | 3 to 8 | 2.5 to 15 |
| Levetiracetam | Immediately before oral dose | 0.2 | 1 to 2 | 12 to 46 |
| 10-Hydroxycarbamazepine (pharmacologically active oxcarbazepine) | Immediately before oral dose | 0.2 | 2 to 3 | 3 to 35 |
| Phenobarbital | Immediately before oral dose | 0.2 | 15 to 30 | 10 to 40 |
| Perampanel | Immediately before oral dose | 0.2 | 10 to 19 | 200 to 1000 (µg/L) |
| Phenytoin | Immediately before oral dose | 0.2 | 6 to 21 | 10 to 20 |
| Pregabalin | Immediately before oral dose | 0.2 | 1 to 2 | 2 to 8 |
| Primidone | Immediately before oral dose | 0.2 | 2 to 5 | 5 to 10 |
| Rufinamide | Immediately before oral dose | 0.2 | 1 to 2 | 30 to 40 |

| Antiepileptic Drug | Ideal Sampling Time | Sample Volume (mL) | Time To Steady-state (Days) | Reference Range (mg/L) |
|--------------------|------------------------------|--------------------|-----------------------------|------------------------|
| Stiripentol | Immediately before oral dose | 0.2 | 1 to 3 | 4 to 22 |
| Tiagabine | Immediately before oral dose | 0.2 | 1 to 2 | 20 to 200 (µg/L) |
| Topiramate | Immediately before oral dose | 0.2 | 4 to 7 | 5 to 20 |
| Valproic Acid | Immediately before oral dose | 0.2 | 2 to 4 | 50 to 100 |
| Vigabatrin | Immediately before oral dose | 0.2 | 1 to 2 | 0.8 to 36 |
| Zonisamide | Immediately before oral dose | 0.2 | 9 to 12 | 10 to 40 |

^A If carbamazepine is being introduced for the first time, steady-state is only achieved after 20 days of treatment due to autoinduction.

- Carbamazepine, eslicarbazepine, gabapentin, lacosamide, levetiracetam, pregabalin, rufinamide, tiagabine, valproic acid and vigabatrin exhibit significant diurnal variation, sampling time in relation to dose is critical.
- During therapy with primidone, monitoring of only the active metabolite phenobarbital is recommended in most circumstances.

All tests are available for blood (plasma or serum) and saliva. All antiepileptic drug assays are available as total plasma or serum concentrations or as free non-protein-bound concentrations.